Summary
Datamonitor's H Lundbeck A/S - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.
H. Lundbeck (Lundbeck) is a specialist pharmaceutical company that focuses solely on the treatment of diseases of the central nervous system (CNS). The company primarily operates in the US and Europe. The company is headquartered in Copenhagen, Denmark and employs more than 5,300 people. The company recorded revenues of DKK 10,984.9 million (approximately $2,021.1 million) during the fiscal year ended December 2007, an increase of 19.1% over 2006. The increase was due to the increasing sales of Cipralex, Azilect and Serdolect. The operating profit of the company was DKK2,695.4 million (approximately $495.9 million) during fiscal year 2007, an increase of 51% over 2006. The net profit was DKK1,769.5 million (approximately $325.6 million) in fiscal year 2007, an increase of 59.8% over 2006.
Scope of the Report
- Provides all the crucial company information required for business and competitor intelligence needs
- Contains a study of the major internal and external factors affecting the company in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams
- Data is supplemented with details on the company's history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available company statement.
Reasons to Purchase
- Support sales activities by understanding your customers' businesses better
- Qualify prospective partners and suppliers
- Keep fully up to date on your competitors' business structure, strategy and prospects
- Obtain the most up to date company information available.
|
